Evaluation of the safety, immunogenicity and efficacy of a new live-attenuated lumpy skin disease vaccine in India.

MLA

Kumar, Naveen, et al. “Evaluation of the Safety, Immunogenicity and Efficacy of a New Live-Attenuated Lumpy Skin Disease Vaccine in India.” Virulence, vol. 14, no. 1, Dec. 2023, p. 2190647. EBSCOhost, https://doi.org/10.1080/21505594.2023.2190647.

APA

Kumar, N., Barua, S., Kumar, R., Khandelwal, N., Kumar, A., Verma, A., Singh, L., Godara, B., Chander, Y., Kumar, G., Riyesh, T., Sharma, D. K., Pathak, A., Kumar, S., Dedar, R. K., Mehta, V., Gaur, M., Bhardwaj, B., Vyas, V., … Tripathi, B. N. (2023). Evaluation of the safety, immunogenicity and efficacy of a new live-attenuated lumpy skin disease vaccine in India. Virulence, 14(1), 2190647. https://doi.org/10.1080/21505594.2023.2190647

Chicago

Kumar, Naveen, Sanjay Barua, Ram Kumar, Nitin Khandelwal, Amit Kumar, Assim Verma, Lokender Singh, et al. 2023. “Evaluation of the Safety, Immunogenicity and Efficacy of a New Live-Attenuated Lumpy Skin Disease Vaccine in India.” Virulence 14 (1): 2190647. doi:10.1080/21505594.2023.2190647.